BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brumec M, Sobočan M, Takač I, Arko D. Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:1642. [PMID: 33915941 DOI: 10.3390/cancers13071642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu B, Natarajan E, Balaji Raghavendran HR, Markandan UD. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. Technol Cancer Res Treat 2023;22:15330338221145246. [PMID: 36601658 DOI: 10.1177/15330338221145246] [Reference Citation Analysis]
2 Khadela A, Chavda VP, Soni S, Megha K, Pandya AJ, Vora L. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. Cancers (Basel) 2022;15. [PMID: 36612226 DOI: 10.3390/cancers15010233] [Reference Citation Analysis]
3 Akhouayri L, Ostano P, Mello-Grand M, Gregnanin I, Crivelli F, Laurora S, Liscia D, Leone F, Santoro A, Mulè A, Guarino D, Maggiore C, Carlino A, Magno S, Scatolini M, Di Leone A, Masetti R, Chiorino G. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. Hum Genomics 2022;16:70. [PMID: 36536459 DOI: 10.1186/s40246-022-00436-6] [Reference Citation Analysis]
4 Long M, You C, Song Q, Hu LXJ, Guo Z, Yao Q, Hou W, Sun W, Liang B, Zhou X, Liu Y, Hu T. AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status. IJMS 2022;23:11468. [DOI: 10.3390/ijms231911468] [Reference Citation Analysis]
5 Gibbs C, So JY, Ahad A, Michalowski AM, Son D, Li Y. CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner. IJMS 2022;23:9314. [DOI: 10.3390/ijms23169314] [Reference Citation Analysis]
6 Jinna N, Rida P, Smart M, Labarge M, Jovanovic-talisman T, Natarajan R, Seewaldt V. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. IJMS 2022;23:8844. [DOI: 10.3390/ijms23168844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ang L, Li J, Dong H, Wang C, Huang J, Li M, Zhao M, Su C, Wu Q. Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer. Bioengineering (Basel) 2022;9:342. [PMID: 35892755 DOI: 10.3390/bioengineering9080342] [Reference Citation Analysis]
8 Skolariki A, D’costa J, Little M, Lord S. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Thompson KJ, Leon-ferre RA, Sinnwell JP, Zahrieh D, Suman V, Metzger F, Asad S, Stover D, Carey L, Sikov W, Ingle J, Liu M, Carter J, Klee E, Weinshilboum R, Boughey J, Wang L, Couch F, Goetz M, Kalari K. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer 2022;4. [DOI: 10.1093/narcan/zcac018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bhatia M, Ahmed R, Nagarajakumar A, Alani A, Doddi S, Metafa A. Measurement of malignant spiculated mass lesions on mammogram: Do we include the length of the spicules? J Can Res Ther 2022;0:0. [DOI: 10.4103/jcrt.jcrt_2052_21] [Reference Citation Analysis]
11 Sun JY, Ni MM. Long non-coding RNA HEIH: a novel tumor activator in multiple cancers. Cancer Cell Int 2021;21:558. [PMID: 34689775 DOI: 10.1186/s12935-021-02272-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. Biomedicines 2021;9:1512. [PMID: 34829741 DOI: 10.3390/biomedicines9111512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kumar S, Freelander A, Lim E. Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers (Basel) 2021;13:4972. [PMID: 34638457 DOI: 10.3390/cancers13194972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Bissanum R, Chaichulee S, Kamolphiwong R, Navakanitworakul R, Kanokwiroon K. Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning. J Pers Med 2021;11:881. [PMID: 34575658 DOI: 10.3390/jpm11090881] [Reference Citation Analysis]